Advertisement

Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced müllerian cancer: a pilot study

      Abstract

      Objective

      The objective of this study was to utilize computed tomographic peritoneography (CTP) to assess distribution prior to intraperitoneal chemotherapy for advanced müllerian cancer.

      Methods

      Nineteen patients were submitted to CTP. A novel 6-point peritoneal distribution index was developed and applied to the patients prospectively.

      Results

      The median peritoneal distribution index was 6 (range, 4–6). The most common region for incomplete peritoneal distribution correlated to the right subphrenic space.

      Conclusion

      Further studies are needed to determine the impact of inadequate distribution on recurrence and survival.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weisberger AS
        • Levine B
        • Storaasli JP
        Use of nitrogen mustard in treatment of serous effusions of neoplastic origin.
        J Am Med Assoc. 1955; 159: 1704-1707
        • Dedrick RL
        • Myers CE
        • Bungay PM
        • DeVita VT
        Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
        Cancer Treat Rep. 1978; 62: 1-11
        • Markman M
        Intraperitoneal drug delivery of antineoplastics.
        Drugs. 2001; 61: 1057-1065
        • Alberts DS
        • Liu PY
        • Hannigan EV
        • O'Toole R
        • Williams SD
        • Young JA
        • Franklin EW
        • Clarke-Pearson DL
        • Malviya VK
        • DuBeshter B
        Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
        N Engl J Med. 1996; 335: 1950-1955
        • Markman M
        • Bundy BN
        • Alberts DS
        • Fowler JM
        • Clark-Pearson DL
        • Carson LF
        • Wadler S
        • Sickel J
        Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
        J Clin Oncol. 2001; 19: 1001-1007
        • Armstrong DK
        • Bundy B
        • Wenzel L
        • Huang HQ
        • Baergen R
        • Lele S
        • Copeland LJ
        • Walker JL
        • Burger RA
        • Gynecologic Oncology Group
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N Engl J Med. 2006; 354: 34-43
        • National Cancer Institute
        Clinical announcement: intraperitoneal chemotherapy for ovarian cancer. January 4, 2006.
        • Elit L
        • Oliver TK
        • Covens A
        • Kwon J
        • Fung MF
        • Hirte HW
        • Oza AM
        Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
        Cancer. 2007; 109: 692-702
        • Dunnick NR
        • Jones RB
        • Doppman JL
        • Speyer J
        • Myers CE
        Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
        AJR Am J Roentgenol. 1979; 133: 221-223
        • Twardowski ZJ
        • Tully RJ
        • Ersoy FF
        • Dedhia NM
        Computerized tomography with and without intraperitoneal contrast for determination of intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients.
        ASAIO Trans. 1990; 36: 95-103
        • Muggia FM
        • LePoidevin E
        • Jeffers S
        • Russell C
        • Boswell W
        • Morrow CP
        • Curtin J
        • Schlaerth J
        Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography.
        Ann Oncol. 1992; 3: 149-154
        • Hughes PM
        • Zammit-Maempel I
        • Murphy D
        Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer.
        Br J Radiol. 1992; 65: 295-297
        • Yoonessi M
        • Abdel-Dayem HM
        • Shalaby OF
        The use of scintigraphic and contrast peritoneography in gynecologic malignancies.
        Diagn Gynecol Obstet. 1982; 4: 75-78
        • Wahl RL
        • Gyves J
        • Gross BH
        • Cochran M
        • Juni JE
        • Arnstein NB
        • Lahti D
        • Ackermann RJ
        SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution.
        AJR Am J Roentgenol. 1989; 152: 1205-1210
        • de Forni M
        • Boneu A
        • Otal P
        • Martel P
        • Shubinski R
        • Bugat R
        • Lucot H
        Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography.
        Bull Cancer. 1993; 80: 345-350
        • Sugimura K
        • Okizuka H
        • Kaji Y
        • Ishida T
        • Iwanari O
        • Kitao M
        Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
        Clin Nucl Med. 1994; 19: 600-603
        • Piccart MJ
        • Floquet A
        • Scarfone G
        • Willemse PH
        • Emerich J
        • Vergote I
        • Giurgea L
        • Coens C
        • Awada A
        • Vermorken JB
        Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.
        Int J Gynecol Cancer. 2003; 13: 196-203
        • Varia MA
        • Stehman FB
        • Bundy BN
        • Benda JA
        • Clarke-Pearson DL
        • Alvarez RD
        • Long HJ
        • Gynecologic Oncology Group
        Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
        J Clin Oncol. 2003; 21: 2849-2855
        • Young RC
        • Brady MF
        • Nieberg RK
        • Long HJ
        • Mayer AR
        • Lentz SS
        • Hurteau J
        • Alberts DS
        Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study.
        J Clin Oncol. 2003; 21: 4350-4355
        • Frasci G
        • Contino A
        • Iaffaioli RV
        • Mastrantonio P
        • Conforti S
        • Persico G
        Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer.
        Gynecol Oncol. 1994; 52: 154-160
        • Giunta S
        • Venturo I
        • Mottolese M
        • Salzano M
        • Diotallevi F
        • Squillaci S
        • Bigotti A
        • Curcio CG
        • Atlante G
        • Natali PG
        Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology.
        Gynecol Oncol. 1994; 53: 103-108
        • Makhija S
        • Leitao M
        • Sabbatini P
        • Bellin N
        • Almadrones L
        • Leon L
        • Spriggs DR
        • Barakat R
        Complications associated with intraperitoneal chemotherapy catheters.
        Gynecol Oncol. 2001; 81: 77-81
        • Keshaviah P
        • Emerson PF
        • Vonesh EF
        • Brandes JC
        Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis.
        J Am Soc Nephrol. 1994; 4: 1820-1826